These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 9390576)
1. Successful use of boric acid to control azole-refractory Candida vaginitis in a woman with AIDS. Shinohara YT; Tasker SA J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Nov; 16(3):219-20. PubMed ID: 9390576 [No Abstract] [Full Text] [Related]
2. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Ray D; Goswami R; Banerjee U; Dadhwal V; Goswami D; Mandal P; Sreenivas V; Kochupillai N Diabetes Care; 2007 Feb; 30(2):312-7. PubMed ID: 17259500 [TBL] [Abstract][Full Text] [Related]
3. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Sobel JD; Sobel R Expert Opin Pharmacother; 2018 Jun; 19(9):971-977. PubMed ID: 29932786 [TBL] [Abstract][Full Text] [Related]
4. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Sobel JD; Vazquez JA Clin Infect Dis; 1996 Apr; 22(4):726-7. PubMed ID: 8729224 [No Abstract] [Full Text] [Related]
5. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. Iavazzo C; Gkegkes ID; Zarkada IM; Falagas ME J Womens Health (Larchmt); 2011 Aug; 20(8):1245-55. PubMed ID: 21774671 [TBL] [Abstract][Full Text] [Related]
6. Candida lusitaniae as an unusual cause of recurrent vaginitis and its successful treatment with intravaginal boric acid. Silverman NS; Morgan M; Nichols WS Infect Dis Obstet Gynecol; 2001; 9(4):245-7. PubMed ID: 11916183 [TBL] [Abstract][Full Text] [Related]
7. Recurrent vulvovaginal candidiasis. Ringdahl EN Mo Med; 2006; 103(2):165-8. PubMed ID: 16703718 [TBL] [Abstract][Full Text] [Related]
8. Prolonged (3-month) mycological cure rate after boric acid suppositories in diabetic women with vulvovaginal candidiasis. Ray D; Goswami R; Dadhwal V; Goswami D; Banerjee U; Kochupillai N J Infect; 2007 Oct; 55(4):374-7. PubMed ID: 17692922 [TBL] [Abstract][Full Text] [Related]
16. Trends in prescribing for vulvovaginal candidiasis in the United States. McCaig LF; McNeil MM Pharmacoepidemiol Drug Saf; 2005 Feb; 14(2):113-20. PubMed ID: 15386715 [TBL] [Abstract][Full Text] [Related]
17. Fluconazole prevents yeast infections in women with HIV. AIDS Patient Care STDS; 1996 Oct; 10(5):310. PubMed ID: 11361529 [No Abstract] [Full Text] [Related]
18. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Sobel JD; Chaim W; Nagappan V; Leaman D Am J Obstet Gynecol; 2003 Nov; 189(5):1297-300. PubMed ID: 14634557 [TBL] [Abstract][Full Text] [Related]
19. Susceptibility of Candida species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid. Otero L; Fleites A; Méndez FJ; Palacio V; Vázquez F Eur J Clin Microbiol Infect Dis; 1999 Jan; 18(1):59-61. PubMed ID: 10192716 [TBL] [Abstract][Full Text] [Related]
20. Single dose oral fluconazole vs intravaginal terconazole in treatment of Candida vaginitis. Comparison and pilot study. Slavin MB; Benrubi GI; Parker R; Griffin CR; Magee MJ J Fla Med Assoc; 1992 Oct; 79(10):693-6. PubMed ID: 1460451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]